A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a open label, phase Ib/II study. All patients are diagnosed with AML, Eastern
Cooperative Oncology Group (ECOG) performance status 0-3. The purpose of this study is to
evaluate the safety and efficacy of AK117 + azacitidine in subjects with AML.